Loading
IMpower133 was the first trial in decades to lengthen survival in extensive-stage small-cell lung cancer, by adding immunotherapy to chemotherapy.
Median OS 12.3 vs 10.3 months (HR 0.70); PFS 5.2 vs 4.3 months. Established chemo-immunotherapy as first-line standard (FDA March 2019). The IMbrella A extension reported the first five-year survival data for chemo-immunotherapy in ES-SCLC, with a small tail of long-term survivors in the atezolizumab arm. Benefit was independent of PD-L1 and TMB.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
403 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Atezolizumab + CE | 201 | 12.3 months | 0.7 (0.54 to 0.91) | 0.007 | link |
| Placebo + CE | 202 | 10.3 months | ||||
| Progression-free survivalprimary | Atezolizumab + CE | - | 5.2 months | 0.77 (0.62 to 0.96) | - | link |
| Placebo + CE | - | 4.3 months |
Immunotherapy is now part of first-line treatment for extensive-stage small-cell lung cancer everywhere, on the strength of a gain measured in weeks. The size of that gain is the reason small-cell lung cancer remains the clearest unmet need in thoracic oncology.
This is the paper Europe PMC returns for registry id NCT02763579 with the most citations, so it is the natural first reading for anyone following the IMpower133 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer, CAPSTONE-1, Platinum + etoposide (EP / CE), Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN).
Shares CAPSTONE-1, Platinum + etoposide (EP / CE), Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Platinum + etoposide (EP / CE), Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer.
Shares Atezolizumab, Roche / Genentech, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer, Extensive-stage small-cell lung cancer, Small-cell lung cancer, Lung cancer (all types).
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.